Wuwei Feng, MD
Neurology · Charleston, SCNPI 1497836076
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,770 of the $16,685 with a category attached, or 64.6%. Ipsen Pharma SAS accounts for 67.9% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $10,532, 6.5 times the $1,608 reported in 2019.
Across 19 payments — averaging $878.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Pharma SAS$11K
- Ipsen Biopharmaceuticals, Inc$5K
- Microtransponder, Inc.$72
Across 47 payments — averaging $2087.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$98K
What the payments were for
- Consulting fees$5,17031%
- Travel & lodging$10,77065%
- Food & beverage$7444%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Pharma SAS | 12 | $11,321 |
| Ipsen Biopharmaceuticals, Inc | 6 | $5,292 |
| Microtransponder, Inc. | 1 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$16,088
- ONIVYDE$730
- SOMATULINE DEPOT$730
How this compares
$16,685 in reported general payments places this provider in the 80th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 12 | $285 |
| Levetiracetam | 15 | $260 |
| Famotidine | 11 | $64 |
| Amlodipine Besylate | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charleston
- Robert AdamsCharleston$204K
- Sarah BreevoortCharleston$90K
- Tanya TuranCharleston$77K
- Katherine RuzhanskyCharleston$52K
- Jonathan HalfordCharleston$48K
- Andrew KeeganCharleston$48K
- Aljoeson WalkerCharleston$35K
- Hamid BahadoriCharleston$29K
- Bruce OvbiageleCharleston$27K
- Andrew AmeriCharleston$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.